The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways
Abstract
Somatic mutations of the receptor tyrosine kinase Flt3 consisting of internal tandem duplications (ITD) occur in 20% of patients with acute myeloid leukemia. They are associated with a poor prognosis of the disease. In this study, we characterized the oncogenic potential and signaling properties of Flt3 mutations. We constructed chimeric molecules that consisted of the murine Flt3 backbone and a 510-base pair human Flt3 fragment, which contained either 4 different ITD mutants or the wild-type coding sequence. Flt3 isoforms containing ITD mutations (Flt3-ITD) induced factor-independent growth and resistance to radiation-induced apoptosis in 32D cells. Cells containing Flt3-ITD, but not those containing wild-type Flt3 (Flt3-WT), formed colonies in methylcellulose. Injection of 32D/Flt3-ITD induced rapid development of a leukemia-type disease in syngeneic mice. Flt3-ITD mutations exhibited constitutive autophosphorylation of the immature form of the Flt3 receptor. Analysis of the involved signal transduction pathways revealed that Flt3-ITD only slightly activated the MAP kinases Erk1 and 2 and the protein kinase B (Akt) in the absence of ligand and retained ligand-induced activation of these enzymes. However, Flt3-ITD led to strong factor-independent activation of STAT5. The relative importance of the STAT5 and Ras pathways for ITD-induced colony formation was assessed by transfection of dominant negative (dn) forms of these proteins: transfection of dnSTAT5 inhibited colony formation by 50%. Despite its weak constitutive activation by Flt3-ITD, dnRas also strongly inhibited Flt3-ITD–mediated colony formation. Taken together, Flt3-ITD mutations induce factor-independent growth and leukemogenesis of 32D cells that are mediated by the Ras and STAT5 pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Small, D., Levenstein, M., Kim, E., Carow, C., Amin, S., Rockwell, P., Witte, L., Burrow, C., Ratajczak, M. Z., & Gewirtz, A. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.2.459 · Cited by 429
Cited by
The role of FLT3 in haematopoietic malignancies
Stirewalt, D. L., & Radich, J. P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1169 · Cited by 865
Mizuki, M., Schwäble, J., Steur, C., Choudhary, C., Agrawal, S., Sargin, B., Steffen, B., Matsumura, I., Kanakura, Y., Böhmer, F. D., et al. (2003) · Blood · doi:10.1182/blood-2002-06-1677 · Cited by 298
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions
Antar, A. I., Otrock, Z. K., Jabbour, E., Mohty, M., & Bazarbachi, A. (2020) · Leukemia · doi:10.1038/s41375-019-0694-3 · Cited by 243
Brandts, C. H., Sargin, B., Rode, M., Biermann, C., Lindtner, B., Schwäble, J., Buerger, H., Müller-Tidow, C., Choudhary, C., McMahon, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0422 · Cited by 212
Self-citationFortelny, N., & Bock, C. (2020) · Genome Biology · doi:10.1186/s13059-020-02100-5 · Cited by 135
NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia
Gerloff, D., Grundler, R., Wurm, A. A., Bräuer-Hartmann, D., Katzerke, C., Hartmann, J.-U., Madan, V, Müller-Tidow, C., Duyster, J., Tenen, D. G., et al. (2015) · Leukemia · doi:10.1038/leu.2014.231 · Cited by 135
The C/EBPδ tumor suppressor is silenced by hypermethylation in acute myeloid leukemia
Agrawal, S., Hofmann, W.-K., Tidow, N., Ehrich, M., Boom, D. V. D., Koschmieder, S., Berdel, W. E., Serve, H., & Müller-Tidow, C. (2007) · Blood · doi:10.1182/blood-2006-08-040147 · Cited by 119
Self-citationCo-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia
Sujobert, P., Poulain, L., Paubelle, E., Zylbersztejn, F., Grenier, A., Lambert, M., Townsend, E. C., Brusq, J.-M., Nicodeme, E., Decrooqc, J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.063 · Cited by 114
Hayakawa, F., Sugimoto, K., Harada, Y., Hashimoto, N., Ohi, N., Kurahashi, S., & Naoe, T. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.63 · Cited by 108
Chu, S. H., Heiser, D., Li, L., Kaplan, I., Collector, M., Huso, D., Sharkis, S. J., Civin, C., & Small, D. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.05.027 · Cited by 79
Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPα
Radomska, H. S., Alberich-Jordà, M., Will, B., Gonzalez, D., Delwel, R., & Tenen, D. G. (2012) · Journal of Clinical Investigation · doi:10.1172/jci43354 · Cited by 67
Metadata
- Authors
- Mizuki, M., Fenski, R., Halfter, H., Matsumura, I., Schmidt, R., Müller, C., Grüning, W., Kratz-Albers, K., Serve, S., Steur, C., Büchner, T., Kienast, J., Kanakura, Y., Berdel, W. E., & Serve, H.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2000-12-01
- Volume
- 96
- Issue
- 12
- Pages
- 3907-3914
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1542395305
- Cited by
- 606
- References
- 1
- FWCI
- 14.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
